Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-001810-14
    Sponsor's Protocol Code Number:PSV-FAI-001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2013-09-19
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2013-001810-14
    A.3Full title of the trial
    A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
    Studio di Fase III, Multinazionale, Multicentrico, Randomizzato, con Mascheramento, Controllato di Sicurezza ed Efficacia di un Inserto Intravitreale di Fluocinolone Acetonide (FAI) in Soggetti affetti da Uveite non Infettiva Cronica che interessa il segmento posteriore dell'occhio.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical study of the FAI Insert in patients with uveitis in the back of the eye that is not caused by an infection
    Studio clinico di un Inserto Intravitreale di FAI in Soggetti affetti da Uveite non Infettiva Cronica che interessa il segmento posteriore dell'occhio.
    A.4.1Sponsor's protocol code numberPSV-FAI-001
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01694186
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorpSivida Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportpSivida Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationpSivida Corporation
    B.5.2Functional name of contact pointClinical Information
    B.5.3 Address:
    B.5.3.1Street Address400 Pleasant Street
    B.5.3.2Town/ cityWatertown
    B.5.3.3Post codeMA 02472
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1617972-6350
    B.5.5Fax number+1617926-5050
    B.5.6E-mailclinical.info@psivida.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Iluvien
    D.2.1.1.2Name of the Marketing Authorisation holderAlimera Sciences Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFluocinolone Acetonide Intravitreal insert
    D.3.2Product code FAI insert
    D.3.4Pharmaceutical form Intravitreal implant in applicator
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravitreal use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUOCINOLONE ACETONIDE
    D.3.9.1CAS number 67-73-2
    D.3.9.4EV Substance CodeSUB07714MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.18
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    chronic non-infectious uveitis affecting the posterior segment of the eye
    Uveite non Infettiva Cronica che interessa il segmento posteriore dell'occhio.
    E.1.1.1Medical condition in easily understood language
    Uveitis in the back of the eye that is not caused by an infection
    Uveite nella parte posteriore dell’occhio che non è causata da un’ infezione
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10046851
    E.1.2Term Uveitis
    E.1.2System Organ Class 10015919 - Eye disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives of this study are to evaluate the safety and efficacy of a FAI insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
    Valutare la sicurezza e l'efficacia di un inserto di FAI nella gestione di soggetti affetti da Uveite non Infettiva Cronica che interessa il segmento posteriore dell'occhio.
    E.2.2Secondary objectives of the trial
    Not applicable
    Non applicabile
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Male or non-pregnant female at least 18 years of age at time of consent
    • One or both eyes having a history of recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis > 1 year duration.
    • During the 12 months prior to enrollment (Day 1), the study eye has either received treatment:
    o systemic corticosteroid or other systemic therapies given for at least 3 months, and/or
    o at least 2 intra- or peri-ocular injections of corticosteroid for management of uveitis
    OR the study eye has experienced recurrence:
    o at least 2 separate recurrences of uveitis requiring systemic, intra- or peri-ocular injection of corticosteroid
    • At the time of enrollment (Day1), study eye has < 10 anterior chamber cells/HPF and a vitreous haze ≤ grade 2.
    • Visual acuity of study eye is at least 15 letters on the ETDRS chart
    • Subject is not planning to undergo elective ocular surgery during the study
    • Subject has ability to understand and sign the Informed Consent Form
    • Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
    • Soggetti di sesso maschile o femminile non in gravidanza di almeno18 anni compiuti al momento del consenso
    • Uno o entrambi gli occhi con anamnesi di uveite non infettiva ricorrente che interessa il segmento posteriore dell'occhio associata o meno a uveite anteriore di durata > 1 anno
    • Durante i 12 mesi che precedono l'arruolamento (Giorno 1),
    l'occhio oggetto di studio ha ricevuto trattamento:
    • con corticosteroidi sistemici o altre terapie sistemiche somministrate per almeno 3 mesi, e/o
    • almeno 2 somministrazioni intra- o peri-oculari di corticosteroide per la gestione dell'uveite
    OPPURE l'occhio oggetto di studio ha manifestato recidiva:
    • almeno 2 episodi distinti di recidiva di uveite che abbiano richiesto iniezione sistemica, intra- o peri-oculare di corticosteroide
    • Al momento dell'arruolamento (Giorno 1), l'occhio oggetto di studio presenta < 10 cellule in camera anteriore/HPF e un'opacità del vitreo ≤ grado 2.
    • L'acuità visiva dell'occhio oggetto di studio è di almeno 15 lettere sul grafico ETDRS
    • Il soggetto non sta programmando di sottoporsi a un intervento chirurgico elettivo nel corso dello studio
    • Il soggetto è in grado di comprendere e firmare il Modulo di Consenso Informato
    • Il soggetto è disposto a ed è in grado di attenersi alle visite programmate, al programma di trattamento, esami di laboratorio ed altre procedure dello studio
    E.4Principal exclusion criteria
    • Allergy to fluocinolone acetonide or any component of the FAI insert
    • History of posterior uveitis only that is not accompanied by vitritis or macular edema
    • History of iritis only and no vitreous cells, anterior chamber cells or vitreous haze
    • Uveitis with infectious etiology
    • Vitreous hemorrhage
    • Intraocular inflammation associated with a condition other than noninfectious uveitis (e.g. intraocular lymphoma)
    • Ocular malignancy in either eye, including choroidal melanoma
    • Toxoplasmosis scar in study eye; or scar related to previous viral retinitis
    • Previous viral retinitis
    • Media opacity precluding evaluation of retina and vitreous
    • Peripheral retinal detachment in area of insertion
    • Current diagnosis of any form of glaucoma
    • Intraocular pressure (IOP) > 21 mmHg or concurrent therapy at screening with any IOP-lowering agent in the study eye
    • Chronic hypotony (< 6 mmHg)
    • Ocular surgery on the study eye within 3 months prior to study Day 1
    • Capsulotomy in study eye within 30 days prior to study Day 1
    • Prior intravitreal treatment of study eye with Retisert within 36 months prior to study Day 1
    • Prior intravitreal treatment of study eye with Ozurdex within 6 months prior to study Day 1
    • Prior intravitreal treatment of study eye with Triesence or Trivaris within 3 months prior to study Day 1
    • Prior peri-ocular or subtenon steroid treatment of study eye within 3 months prior to study Day 1
    • Subjects requiring chronic systemic or inhaled corticosteroid therapy (>15mg prednisone daily) or systemic immunosuppressive therapy to manage non-ocular disease
    • Excluding certain skin cancers (specifically, basal cell carcinoma and squamous cell carcinoma), any malignancy receiving treatment, or in remission less than 5 years prior to study Day 1
    • Subjects who have tested positive for human immune deficiency virus (HIV)
    • Systemic infection within 30 days prior to study Day 1
    • Any severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, could make the subject inappropriate for entry into this study
    • Any other systemic or ocular condition which, in the judgment of the investigator, could make the subject inappropriate for entry into this study
    • Treatment with an investigational drug or device within 30 days prior to study Day 1
    • Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to study Day 1 until the Month 12 Visit
    • Subjects unlikely to comply with the study protocol or who are likely to be lost to follow-up within three years
    • Allergia al fluocinolone acetonide o a qualsiasi componente dell'inserto di FAI
    • Anamnesi di sola uveite posteriore non accompagnata da vitrite o edema maculare
    • Anamnesi di sola irite e assenza di cellule vitree, cellule in camera anteriore o opacità del vitreo
    • Uveite con eziologia infettiva
    • Emorragia vitreale
    • Infiammazione intraoculare associata a una condizione diversa da uveite non infettiva (per esempio linfoma intraoculare)
    • Tumore maligno oculare in uno degli occhi, incluso melanoma della coroide
    • Cicatrice da toxoplasmosi nell'occhio oggetto di studio o cicatrice correlata a precedente retinite virale.
    • Precedente retinite virale
    • Opacità del mezzo oculare che impedisce la valutazione della retina e del corpo vitreo.
    • Distacco periferico della retina nell'area di inserzione
    • Diagnosi attuale di glaucoma di qualsiasi forma
    • Pressione intraoculare (IOP) > 21 mmHg o terapia concomitante allo Screening con qualsiasi agente IOP-riducente nell'occhio oggetto di studio
    • Ipotonia cronica (< 6 mmHg)
    • Intervento chirurgico oculare all'occhio oggetto di studio entro i 3 mesi che precedono il Giorno 1 dello studio.
    • Capsulotomia nell'occhio oggetto di studio entro 30 giorni prima del Giorno 1 dello studio
    • Precedente trattamento intravitreale dell'occhio oggetto di studio con Retisert entro i 36 mesi che precedono il Giorno 1 dello studio.
    • Precedente trattamento intravitreale dell'occhio oggetto di studio con Ozurdex entro i 6 mesi che precedono il Giorno 1 dello studio.
    • Precedente trattamento intravitreale dell'occhio oggetto di studio con Triesence o Trivaris entro i 3 mesi che precedono il Giorno 1 dello studio.
    • Precedente trattamento perioculare o subtenon con steroide dell'occhio oggetto di studio entro i 3 mesi che precedono il Giorno 1 dello studio.
    • Soggetti che richiedono terapia cronica con corticosteroidi sistemici o per inalazione (>15mg di prednisone giornalieri) o terapia immunosoppressiva sistemica per gestire una malattia non oculare.
    • Esclusi alcuni tumori della pelle (in particolare carcinoma delle cellule basali e carcinoma squamocellulare), qualsiasi tumore maligno che riceva trattamento o in remissione da meno di 5 anni prima del Giorno 1 dello Studio.
    • Soggetti che hanno avuto un risultato positivo al test del virus dell'immunodeficienza umana (HIV)
    • Infezione sistemica entro 30 giorni prima del Giorno 1 dello Studio.
    • Qualsiasi grave condizione clinica o psichiatrica acuta o cronica che potrebbe aumentare il rischio associato alla partecipazione allo studio o potrebbe interferire con l'interpretazione dei risultati dello studio e, a giudizio dello sperimentatore, potrebbe rendere il soggetto non idoneo all'ingresso in questo studio
    • Qualsiasi altra condizione sistemica od oculare che, a giudizio dello sperimentatore, potrebbe rendere il soggetto non idoneo all'ingresso in questo studio
    • Trattamento con un farmaco o dispositivo sperimentale entro 30 giorni prima del Giorno 1 dello Studio.
    • Soggetti di sesso femminile in gravidanza o allattamento; soggetti di sesso femminile in età fertile non disposte o non in grado di usare un metodo di contraccezione accettabile come delineato in questo protocollo da almeno 14 giorni prima del Giorno 1 dello Studio fino alla visita del Mese 12
    • Soggetti che probabilmente non si atterranno al protocollo di studio o che probabilmente saranno persi al follow-up entro tre anni.
    E.5 End points
    E.5.1Primary end point(s)
    Efficacy:
    Proportion of subjects who have a recurrence of uveitis in the study eye within 12 months after receiving study treatment.
    Recurrence is defined as:
    • A > 2 step increase in the number of cells in the anterior chamber per high powered field (1.6 X using a 1-mm beam), compared to any visit time point prior to Month 12
    OR
    • An increase in the vitreous haze of > 2 steps, compared to any visit time point prior to Month 12
    OR
    • A deterioration in visual acuity of at least 15 letters BCVA, compared to any visit time point prior to Month 12

    Safety:
    • Systemic adverse events
    • Ocular adverse events, including IOP elevation; medications/procedures required to control elevated IOP; development or worsening of cataract; cataract-related procedures; clinically significant ocular changes; procedure related adverse events
    Efficacia
    Percentuale di soggetti che presentano una recidiva di uveite nell'occhio oggetto di studio entro 12 mesi dopo aver ricevuto il trattamento in studio. La recidiva è definita come:
    • Un incremento > 2 stadi del numero di cellule nella camera anteriore per campo ad alta potenza (1,6 X usando un raggio di 1-mm ), messo a confronto con qualsiasi momento temporale di visita prima del Mese 12.
    OPPURE
    • Un aumento dell'opacità del vitreo di > 2 stadi, rispetto a qualsiasi momento temporale di visita prima del Mese 12
    OPPURE
    • Un peggioramento dell'acuità visiva di almeno 15 lettere BCVA rispetto a qualsiasi momento temporale di visita prima del Mese 12

    Sicurezza
    • Eventi avversi sistemici
    • Eventi avversi oculari, incluso aumento dell'IOP, trattamento farmacologico /procedure necessari per il controllo della IOP elevata; sviluppo o peggioramento di cataratta, procedure correlate alla cataratta; variazioni oculari clinicamente rilevanti; eventi avversi correlati alla procedura
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 months after receiving study treatment
    12 mesi dopo l’assunzione del trattamento dello studio
    E.5.2Secondary end point(s)
    Exploratory Efficacy Endpoints:
    • Proportion of subjects who have a recurrence of uveitis in the study eye within 36 months
    • Proportion of subjects who have a recurrence of uveitis in the fellow eye (within 12 months and 36 months)
    • Mean change from baseline in BCVA letter score in the study eye (at 12 months and 36 months)
    • Number of recurrences of uveitis (within 12 months and 36 months)
    • Time to recurrence of uveitis (within 12 months and 36 months)
    • Number of adjunctive treatments required to treat recurrences of uveitis (within 12 months and 36 months)
    • Resolution of macular edema, as measured by OCT imaging (at 12 months and 36 months)
    Endpoint di Efficacia Esplorativi:
    • Percentuale di soggetti che presentano una recidiva di uveite nell'occhio oggetto di studio entro 36 mesi.
    • Percentuale di soggetti che presentano una recidiva di uveite nell'altro occhio (entro 12 mesi e 36 mesi).
    • Variazione media rispetto al basale del punteggio delle lettere BCVA nell'occhio oggetto di studio (a 12 mesi e 36 mesi)
    • Numero di recidive di uveite (entro 12 mesi e 36 mesi)
    • Tempo alla recidiva di uveite (entro 12 mesi e 36 mesi)
    • Numero di trattamenti aggiuntivi necessari per trattare le recidive di uveite (entro 12 mesi e 36 mesi)
    • Risoluzione di edema maculare misurata mediante imaging OCT (a 12 mesi e 36 mesi)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Within 12 and/or 36 months after receiving study treatment
    Entro 12 e/o 36 mesi dopo l’assunzione del trattamento dello studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Iniezione fittizia
    Sham Injection
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA27
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    India
    Israel
    Turkey
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita dell'ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The sponsor is considering the possibility of offering subjects who complete PSV-FAI-001 additional treatment with the FAI insert, in the study eye, the fellow eye or both eyes, depending upon the disease status of the subject's eyes. The company will make a decision in the future concerning this possible additional study, based on many factors, including the efficacy and safety of the FAI insert observed in PSV-FAI-001
    Lo Sponsor sta considerando la possibilità di offrire ai soggetti che completano PSV FAI 001 un trattamento aggiuntivo con l’Inserto FAI nell’occhio in studio, l’altro occhio o entrambi gli occhi, in base allo stato della malattia degli occhi del soggetto. Lo Sponsor prenderà la decisione in futuro per la possibilità di questo studio aggiuntivo,sulla base di molti fattori, comprese l’efficacia e la sicurezza dell’ Inserto Intravitreale di Fluocinolone Acetonide osservate nello studio PSV FAI 001
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-10-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-10-08
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 17:09:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA